Profil
Warren Thomas Brown served as a Non-Executive Director at Mesa Minerals Ltd.
in 2010, at CBio Ltd.
in 2011, and as an Independent Non-Executive Director at Invion Ltd.
from 2013 to 2018.
Anciens postes connus de Warren Thomas Brown
| Sociétés | Poste | Fin |
|---|---|---|
| INVION LIMITED | Directeur/Membre du Conseil | 22/03/2018 |
CBio Ltd.
 CBio Ltd. BiotechnologyHealth Technology CBio Ltd. focuses on developing new generation products for the treatment of autoimmune and inflammatory diseases. It develops and commercializes treatments for autoimmune diseases. The company focuses and develops technologies on commercializing its proprietary drug, XToll for autoimmune and inflammatory diseases. It develops technologies for the treatment of autoimmune and inflammatory diseases. The company also engages in the business of research, product development and clinical trials of the therapeutic drug XToll and development of variants to the company's Cpn10 technology. CBio was founded by Steve P. Jones on October 11, 2000 and is headquartered at Brisbane, Australia. | Directeur/Membre du Conseil | 29/11/2011 |
| MESA MINERALS LIMITED | Directeur/Membre du Conseil | 22/06/2010 |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| INVION LIMITED | Health Technology |
| Entreprise privées | 2 |
|---|---|
Mesa Minerals Ltd.
 Mesa Minerals Ltd. Other Metals/MineralsNon-Energy Minerals Mesa Minerals Ltd. engages in hydrometallurgical process technology. Its products includes electrolytic manganese dioxide, electrolytic manganese metal, micro nutrient, granulated manganese sulfate, and manganese ore. The company was founded on October 26, 1984 and is headquartered in Applecross, Australia. | Non-Energy Minerals |
CBio Ltd.
CBio Ltd. BiotechnologyHealth Technology CBio Ltd. focuses on developing new generation products for the treatment of autoimmune and inflammatory diseases. It develops and commercializes treatments for autoimmune diseases. The company focuses and develops technologies on commercializing its proprietary drug, XToll for autoimmune and inflammatory diseases. It develops technologies for the treatment of autoimmune and inflammatory diseases. The company also engages in the business of research, product development and clinical trials of the therapeutic drug XToll and development of variants to the company's Cpn10 technology. CBio was founded by Steve P. Jones on October 11, 2000 and is headquartered at Brisbane, Australia. | Health Technology |